首页> 外文期刊>Life sciences >Epigenetics-based therapeutics for myocardial fibrosis
【24h】

Epigenetics-based therapeutics for myocardial fibrosis

机译:基于表观学的纤维化治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

Myocardial fibrosis (MF) is a reactive remodeling process in response to myocardial injury. It is mainly manifested by the proliferation of cardiac muscle fibroblasts and secreting extracellular matrix (ECM) proteins to replace damaged tissue. However, the excessive production and deposition of extracellular matrix, and the rising proportion of type I and type III collagen lead to pathological fibrotic remodeling, thereby facilitating the development of cardiac dysfunction and eventually causing heart failure with heightened mortality. Currently, the molecular mechanisms of MF are still not fully understood. With the development of epigenetics, it is found that epigenetics controls the transcription of pro-fibrotic genes in MF by DNA methylation, histone modification and noncoding RNAs. In this review, we summarize and discuss the research progress of the mechanisms underlying MF from the perspective of epigenetics, including the newest m6A modification and crosstalk between different epigenetics in MF. We also offer a succinct overview of promising molecules targeting epigenetic regulators, which may provide novel therapeutic strategies against MF.
机译:心肌纤维化是心肌损伤后的反应性重塑过程。主要表现为心肌成纤维细胞增殖,分泌细胞外基质(ECM)蛋白替代受损组织。然而,细胞外基质的过度产生和沉积,以及I型和III型胶原比例的增加,导致病理性纤维化重塑,从而促进心功能不全的发展,最终导致心力衰竭,死亡率升高。目前,MF的分子机制还不完全清楚。随着表观遗传学的发展,人们发现表观遗传学通过DNA甲基化、组蛋白修饰和非编码RNA控制MF中促纤维化基因的转录。本文从表观遗传学的角度综述和讨论了MF相关机制的研究进展,包括最新的m6A修饰和MF不同表观遗传学之间的相互作用。我们还简要概述了靶向表观遗传调节因子的有前途的分子,这可能为MF提供新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号